Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.71 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.71 |
| ▸ | AKR1C3 | P42330 | 12/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 12/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23566793 | 0.87 | CPN1 (0.67) | CPN1CPB2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6550969 | 0.84 | CPN1 (0.68) | CPN1CPB2ALDH1A1MEN1KMT2A | |
| SCHEMBL2352530 | 0.83 | CPN1 (1.00) | CPN1CPB2PBRM1LMNAMEN1 | |
| SCHEMBL31478057 | 0.82 | CPN1 (0.53) | CPN1CPB2LMNAMEN1KMT2A | |
| SCHEMBL2079660 | 0.82 | CPN1 (0.49) | CPN1CPB2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL28032981 | 0.82 | AKR1C3 (0.46) | CPN1CPB2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1801772 | 0.81 | AKR1C3 (0.52) | CPN1CPB2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1820061 | 0.81 | KYNU (0.51) | CPN1CPB2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1653534 | 0.81 | AKR1C3 (0.52) | CPN1CPB2AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29687004 | 0.81 | KYNU (0.51) | CPN1CPB2AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3059004-B1 | METHOD FOR REMOVING SOX FROM GAS WITH COMPLEX ALCOHOL-AMINE SOLUTION | BEIJING BOYUAN HENGSHENG HIGH TECH CO LTD (CN) | 2021-06-30 | — | — | EP | claimed |
| US-9999852-B2 | Method for removing SOx from gas with compound alcohol-amine solution | BEIJING BOYUAN HENGSHENG HIGH-TECHNOLOGY CO., LTD (CN) | 2018-06-19 | — | — | US | claimed |
| US-20160243491-A1 | Method for Removing SOx from Gas with Compound Alcohol-Amine Solution | PEKING UNIVERSITY (CN) | 2016-08-25 | — | — | US | claimed |
| EP-3059004-A1 | METHOD FOR REMOVING SOX FROM GAS WITHNCOMPOUND ALCOHOL-AMINE SOLUTION | Beijing Boyuan-Hengsheng High-Technology Co., Ltd. (CN) | 2016-08-24 | — | — | EP | claimed |
| CN-103495340-B | The method of SOx in compound alcamines solution removal gas | BEIJING BOYUAN HENGSHENG HIGH-TECHNOLOGY CO.,LTD. (CN) | 2015-11-18 | — | — | CN | claimed |
| CN-103495340-A | Method of removing SOx in gas by compound alkanolamine solution | BEIJING BOYUAN HENGSHENG HIGH TECHNOLOGY CO LTD | 2014-01-08 | — | — | CN | claimed |
| CN-119930496-A | Preparation method of 2- [4- (1-oxo-2-isoindolinyl) phenyl ] butyric acid | 山东诚成医药科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119395197-A | Detection method of genotoxic impurity o-methylbenzaldehyde in indobufen | 湖南方盛制药股份有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-116297908-B | Analysis method of indobufen isomer impurity | 湖南九典制药股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-116297908-A | Analysis method of indobufen isomer impurity | 湖南九典制药股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3059004-B1 | METHOD FOR REMOVING SOX FROM GAS WITH COMPLEX ALCOHOL-AMINE SOLUTION | BEIJING BOYUAN HENGSHENG HIGH TECH CO LTD (CN) | 2021-06-30 | — | — | EP | disclosed |
| US-9999852-B2 | Method for removing SOx from gas with compound alcohol-amine solution | BEIJING BOYUAN HENGSHENG HIGH-TECHNOLOGY CO., LTD (CN) | 2018-06-19 | — | — | US | disclosed |
| US-20160243491-A1 | Method for Removing SOx from Gas with Compound Alcohol-Amine Solution | PEKING UNIVERSITY (CN) | 2016-08-25 | — | — | US | disclosed |
| CN-103495340-B | The method of SOx in compound alcamines solution removal gas | BEIJING BOYUAN HENGSHENG HIGH-TECHNOLOGY CO.,LTD. (CN) | 2015-11-18 | — | — | CN | disclosed |
| CN-103495340-A | Method of removing SOx in gas by compound alkanolamine solution | BEIJING BOYUAN HENGSHENG HIGH TECHNOLOGY CO LTD | 2014-01-08 | — | — | CN | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1996563-B1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-8030308-B2 | Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPN1 830/4885CPB2 2211/4885AKR1C3 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.